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SUMMARY Transcriptomics, the analysis of genome-wide RNA expression, is a com-
mon approach to investigate host and pathogen processes in infectious diseases.
Technical and bioinformatic advances have permitted increasingly thorough analyses
of the association of RNA expression with fundamental biology, immunity, patho-
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genesis, diagnosis, and prognosis. Transcriptomic approaches can now be used to
realize a previously unattainable goal, the simultaneous study of RNA expression in
host and pathogen, in order to better understand their interactions. This exciting
prospect is not without challenges, especially as focus moves from interactions in
vitro under tightly controlled conditions to tissue- and systems-level interactions in
animal models and natural and experimental infections in humans. Here we review
the contribution of transcriptomic studies to the understanding of malaria, a para-
sitic disease which has exerted a major inﬂuence on human evolution and continues
to cause a huge global burden of disease. We consider malaria a paradigm for the
transcriptomic assessment of systemic host-pathogen interactions in humans, be-
cause much of the direct host-pathogen interaction occurs within the blood, a read-
ily sampled compartment of the body. We illustrate lessons learned from transcrip-
tomic studies of malaria and how these lessons may guide studies of host-pathogen
interactions in other infectious diseases. We propose that the potential of transcrip-
tomic studies to improve the understanding of malaria as a disease remains partly
untapped because of limitations in study design rather than as a consequence of
technological constraints. Further advances will require the integration of transcrip-
tomic data with analytical approaches from other scientiﬁc disciplines, including epi-
demiology and mathematical modeling.
KEYWORDS RNA sequencing, transcriptomics, apicomplexan parasites, host-parasite
relationship, host-pathogen interactions, immune response, malaria, pathogenesis
INTRODUCTION
Transcriptomics is the quantitative or qualitative study of RNAs on a genome-widescale (1). It is just one of several powerful approaches to undertake comprehensive
or global analyses of large sets of related features, such as genes (genomics), proteins
(proteomics), DNA modiﬁcations (epigenomics), or microbial communities (microbiom-
ics). These approaches are often used for discovery rather than hypothesis-based
investigation, since they can provide an unbiased description of similarities or differ-
ences between conditions of interest. The development of technologies for these
high-dimensional analyses has been accompanied by novel computational and analytic
approaches to deal with the vast amounts of data and has driven the emergence of the
scientiﬁc discipline of bioinformatics (2).
Initially, transcriptomic studies sought to quantify the expression levels of protein-
encoding genes, often with the implicit assumption that this would broadly indicate
changes in protein expression levels (3). However, as technologies and the understand-
ing of noncoding RNAs have evolved, transcriptomic approaches have allowed a much
deeper understanding of the complexities of the regulation of gene expression, alter-
nate splicing events, and functions of noncoding RNAs as well as proving invaluable for
the accurate construction and annotation of complex genomes (4–7). Combinations of
genomic, epigenomic, transcriptomic, and proteomic approaches are now increasingly
being applied to provide a deeper understanding of the multiple layers of control that
result in variations between cells, tissues, individuals, and populations in either health
or disease (1, 7–10).
Malaria
Malaria is a parasitic disease caused by apicomplexan parasites of the genus
Plasmodium, which can infect a diverse range of vertebrate hosts. A comprehensive
description of malaria epidemiology, biology, immunology, pathogenesis, and treat-
ment is beyond the scope of this text and has been covered in recent review articles
(11–16). Here we give a brief overview, and additional background accompanies
relevant sections below in this article.
Five main species of Plasmodium cause most disease in humans: P. falciparum, P.
vivax, P. knowlesi, P. malariae, and P. ovale. P. falciparum is the major cause of severe
malaria, which can result in death, and is the focus of most of the human studies
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discussed in this article. The term malaria refers to the disease caused by infection with
these parasites, and individuals with asexual-stage parasites in their blood without
symptoms are described as having asymptomatic parasitemia (11).
Plasmodium species are transmitted to humans by the bite of female Anopheles
mosquitoes, and motile forms of the parasite (sporozoites) quickly make their way from
the skin to blood vessels to hepatocytes, where they undergo massive intracellular
asexual replication during the incubation phase of infection (Fig. 1). After one or more
FIG 1 Main interactions with human tissues and cells during the Plasmodium falciparum developmental cycle. (1) Infection is initiated by
a mosquito bite. Motile sporozoites rapidly ﬁnd their way past the structural and immune cells in the skin into blood vessels and onwards
to the liver. The short transit time limits opportunities for cellular interactions. (2) Sporozoites reach the liver, exit the vasculature through
Kupffer cells, and then undergo massive replication in hepatocytes. Immune cells such as CD8 T cells patrol the liver and may detect and
kill infected hepatocytes. (3) Parasites burst out of hepatocytes and enter the bloodstream, rapidly infecting erythrocytes. They undergo
repeated cycles of asexual replication, interacting with blood leukocytes. Parasite products are carried throughout the systemic circulation,
triggering inﬂammatory responses. (4) Parasitized red cells may be cleared by the spleen, which is a major location for the host immune
response to Plasmodium. (5) Parasites may exit the asexual erythrocytic cycle to produce gametocytes, which may be taken up by another
mosquito bite to allow onward transmission. Gametocytogenesis may be inﬂuenced by the host response, and most gametocyte
development occurs in the bone marrow. Mature gametocytes reenter and circulate in the blood, potentially interacting with host
leukocytes and the vascular endothelium. (6) Parasites can cause severe disease if they accumulate (sequester) and obstruct the
microvasculature of vital organs, such as the brain. There may be both direct and indirect interactions with the vascular endothelium,
leukocytes, and parenchymal cells.
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weeks, the brood of parasites escapes from the hepatocyte and reenters the blood-
stream, but this time, the parasites rapidly invade red blood cells (RBCs), where they
undergo repeated asexual reproductive cycles, with new parasites being produced
every 24 to 72 h, depending on parasite species (11).
For P. falciparum, around 16 to 32 daughter parasites are released approximately
every 48 h. Parasite numbers increase exponentially until they are sufﬁcient to trigger
a host response, which starts to constrain this growth and also results in symptoms
such as fever, muscle aches, headache, and violent shivering (rigors) (11–13). Often,
symptoms occur in paroxysms, coinciding with the rupture of RBCs and the release of
new parasites and their pathogen-associated molecular patterns into the circulation,
triggering responses through host pattern recognition receptors (16).
If parasite numbers continue to increase, because of insufﬁcient constraint by the
host response or a failure to receive antimalaria treatment, this predisposes an indi-
vidual to an increasing risk of severe disease manifestations, which may include coma,
lung injury, renal failure, acidosis, and severe anemia (11, 13, 16). These manifestations
are thought to be consequences of not only high parasite loads but also high levels of
inﬂammation; dysfunction of the vascular endothelium, which impairs its ability to
regulate blood ﬂow and prevent coagulation; and obstruction of small blood vessels by
adherent parasitized erythrocytes (sequestration) (12, 13, 15, 16).
Indeed, extensive sequestration is a unique feature of P. falciparum and is largely
explained by speciﬁc adhesive interactions between vascular endothelial surface mol-
ecules and parasite molecules expressed on the surface of infected RBCs (iRBCs)
(17–19). However, the parasite will not beneﬁt if inexorable growth kills its host too
quickly, and at some stage in the intraerythrocytic asexual replication cycle, a propor-
tion of parasites begins to differentiate into sexual stages (gametocytes), which can be
taken up in the blood meal of another mosquito (20). The sexual phase of the life cycle
then occurs in the mosquito gut, with a brief diploid stage before new haploid parasites
eventually make their way to the salivary glands as sporozoites, ready to infect a new
human host during a future blood meal (15).
Individuals in some areas where malaria is highly endemic will be exposed to
multiple infectious mosquito bites every day, and cumulative infections result in the
acquisition of clinical immunity. First, individuals cease to be vulnerable to severe
disease, and they then become less likely to develop clinical symptoms (12). This clinical
immunity is thought to be largely antibody mediated and may reﬂect the ability to
reduce, but not completely prevent, parasite replication through the acquisition of an
increasing breadth of antibodies against polymorphic parasite antigens (14, 15, 21).
Naturally acquired sterile immunity is thought to be very rare (perhaps never occur-
ring), and the need to considerably improve on this natural immune response to highly
antigenically diverse parasites has also produced challenges for vaccine development
(14, 15).
Malaria as a Paradigm for Transcriptomic Studies of Systemic Host-Pathogen
Interactions
Clinical manifestations of malaria are due to the asexual blood stage of the parasite,
and the host-parasite interactions that cause disease occur within the vasculature and
its contiguous organs, such as the spleen (13, 16, 22). This means that many aspects of
the host-pathogen interaction can be assessed through analyses of circulating blood.
Whole blood (containing leukocytes and RBCs) can be used as a source of both host
and parasite cells, and transcriptomic analyses can be applied to examine either cell
type (23, 24) or both cell types in the same sample (25). The high numbers of parasites
that can be found in human blood, particularly in children with some forms of severe
malaria (26, 27), can yield abundant parasite RNA, making this a feasible approach.
Furthermore, the pathogen load can be estimated from an examination of blood for
parasites or their products (18, 26–29). In our experience, parasitemia levels as low as
2% can yield sufﬁcient parasite RNA reads for meaningful analysis with standard-depth
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RNA sequencing (RNA-seq) (30 million to 40 million reads), but lower parasitemia levels
may require greater sequencing depth.
The pathogen load is likely to be an important factor in determining the pathogen-
esis of many infectious diseases but is much harder to quantify as a stimulus for the
systemic host response when pathogens are differentially distributed throughout
multiple tissues (30). On a reductionist scale, transcriptomic studies of bacterial infec-
tions in cell culture models have identiﬁed reciprocal interactions between host and
pathogen that contribute to pathogen growth (31, 32), but understanding how this
relates to disease requires evaluation at a much larger scale. Evaluation of host-parasite
interactions in blood in malaria through transcriptomic analyses provides a paradigm
for understanding the role of systemic host-pathogen interactions in general.
Aims and Scope of This Review
Here we aim to describe the contribution that transcriptomic studies have already
made to understanding malaria and highlight how new approaches might permit
greater insights. We provide an introduction to existing and new technologies and
analytical approaches and outline how these technologies are transforming the depth
and richness of transcriptomic data. We then consider malaria as a paradigm for
transcriptional analyses of systemic host-pathogen interactions, lessons learned from
malaria studies, and strategies for application to other infectious diseases. We illustrate
that the traditional approach of considering variation in the host response to an
invariant pathogen is too simplistic and that accumulating evidence suggests that
dynamic variation in pathogen behavior also needs to be considered.
TRANSCRIPTOMIC APPROACHES TO HOST-PATHOGEN INTERACTIONS
There are numerous excellent reviews of transcriptomic technologies, including
comparisons of their relative merits and detailed methodological considerations (4,
33–37), so we highlight only selected characteristics here. The development of these
technologies over the last 2 decades (Fig. 2) has driven many transcriptomic studies of
malaria and other infectious diseases, sometimes with more emphasis on applying new
technology than on addressing important biological and clinical questions. Microarray
technologies were initially the only commercial transcriptomic tools, but they have
never been ideally suited to studies of host-pathogen interactions because of the
limited range of species covered by commercial arrays and the major restriction that
probes must be designed for known or predicted transcripts. Thus, initial microarray
studies focused largely on host gene expression, and as pathogen genomes were
assembled, pathogen gene expression analyses then became possible. Eventually,
attempts were made to study both host and pathogen together by using custom-made
arrays, but these methods never achieved great popularity because of design chal-
lenges. The inherent limitations of microarray technology (Table 1) mean that it is being
superseded by RNA-seq as the preferred approach for many transcriptomic applica-
tions, including studies of infectious diseases.
In theory, RNA-seq is much better suited for studies of host-pathogen interactions,
although this is not always straightforward (31, 56). A major challenge is that the RNA
from the pathogen may comprise only a tiny proportion of the total RNA isolated from
a specimen, particularly in the case of bacterial infection. One solution is to use model
systems, for example, genetically modiﬁed ﬂuorescent pathogens, to allow cell sorting
and selection of infected host cells (31, 32). An alternative is the speciﬁc enrichment of
pathogen transcripts at the time of RNA extraction (32). Additional steps to maximize
the capture of pathogen RNA, for example, enhanced lysis to release both bacterial and
host RNAs from cells, and rRNA depletion to maximize the sequencing of mRNA may
be needed (57).
These approaches have led to the identiﬁcation of host-pathogen interactions at a
cellular scale, such as the regulation of invasion-associated effectors and virulence
genes by bacterial noncoding RNAs (31), but there is an increasing desire to apply dual
RNA-seq to infections in vivo, and deep RNA sequencing is already achieving some
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success (58, 59). This has led to evidence that pathogen gene expression can vary
within the host (59) and can be driven by the host response (58), providing a further
impetus for this approach. Dual RNA-seq has also been applied to viral infections,
allowing virus detection to be coupled to host transcriptome analysis (60), quantiﬁca-
tion of viral loads (61), and detection of variation in viral gene expression levels (62).
FIG 2 Timeline of transcriptomic approaches for infectious diseases. Transcriptomic analysis requires the extraction of RNA from parts of
the body such as peripheral blood. Methods of analysis have evolved over time. Serial analysis of gene expression (SAGE) utilizes the
Sanger sequencing approach to generate and sequence short (11-nucleotide) tags and quantify transcript abundance. It is expensive
and low throughput. Massively parallel signature sequencing (MPSS) generates slightly longer tags (17 to 20 nucleotides) and provides
a larger library size. Cap analysis of gene expression (CAGE) is similar in principle to SAGE but targets transcription start sites. Microarray
analysis is a hybridization approach that uses ﬂuorescence-tagged probes to target transcripts of interest. RNA sequencing (RNA-seq) is
a high-throughput sequencing approach capable of novel transcript discovery, noncoding RNA analysis, and alternative splicing analysis.
RNA-seq has been developed to allow transcriptomic analysis at a single-cell resolution, simultaneous analysis of host and pathogen
transcriptomes (dual RNA-seq), and sequencing of full-length transcripts to allow detailed analysis of transcript isoforms and direct analysis
of RNA. In the future, techniques such as laser capture microdissection (LCM) may be coupled with RNA-seq to allow host cells and their
interacting pathogens (such as parasites adhering to vascular endothelial cells) to be isolated and studied as deﬁned cell groups or dual
single-cell analyses. Massively parallel single-cell analyses and direct RNA-seq are also on the horizon.
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Eukaryotic pathogens generally contain more RNA and may have a greater capacity
to change their gene expression in response to their host. Feasibility has been dem-
onstrated, for example, in the gut of mice infected with whipworm (63) and the blood
of P. falciparum-infected malaria patients (where about 10% of whole-blood reads
mapped to the parasite) (25). In contrast, dual RNA-seq of brain tissue from mice
infected with a different apicomplexan parasite, Toxoplasma gondii, showed a much
lower proportion of reads (around 0.1%) mapping to the parasite genome (64), which
likely reﬂects the very low abundance of parasite relative to host cells. Similarly,
systemic infection with Candida albicans yielded so little fungal RNA from mouse
kidneys that speciﬁc enrichment was necessary for pathogen RNA-seq (65). Therefore,
obtaining appropriate data for simultaneous host and pathogen transcriptomic studies
is highly dependent on the pathogen, the RNA content per pathogen, the sample type,
and the pathogen load.
TRANSCRIPTOMIC STUDIES OF MALARIA
What Transcriptomic Studies Have Been Done on Malaria?
There are many transcriptomic studies of Plasmodium species in vitro and in vivo.
Here we focus primarily on those using samples from humans with P. falciparum
malaria and animal models of human infection, and we draw upon pivotal in vitro
studies, where necessary, to give context. Recent reviews have addressed the applica-
tion of transcriptomics to speciﬁc aspects of malaria immunology, vaccinology, and
TABLE 1 Comparison of microarray and RNA sequencing technologies
Feature
Description
Reference(s)Microarray RNA sequencing
Technology Tens of thousands of DNA probes speciﬁc for
each transcript of interest within
microwells on a chip; capture of cDNA
produces a ﬂuorescent signal proportional
to target abundance
Next-generation sequencing of many millions
of cDNA fragments
4, 38
Reference genome dependent Yes; probes must be designed for speciﬁc
targets
No; de novo assembly of transcripts is
possible, reference is helpful for
quantiﬁcation
4, 38
Sample requirement(s) Good-quality, nondegraded RNA Good-quality, nondegraded RNA but possible
with small amounts and partially degraded
samples; rRNA depletion is usually required
37, 39
Dynamic range for transcript
detection
Fixed Unlimited but inﬂuenced by sequencing read
depth
40
Novel transcript detection No Yes 41, 42
Noncoding RNA detection Yes Yes 41–43
Splice detection Yes but limited to known splice sites Yes 44, 45
Dual host-pathogen transcript
detection
Yes but requires custom arrays designed for
both transcriptomes
Yes; relative amounts of RNA determine
detection limits
32, 46
Quantiﬁcation of gene expression Analogue Digital 4, 38
Analysis Widely accessible with user-friendly software
packages
More challenging; often requires a
bioinformatician
34, 47, 48
Cost Relatively cheap overall; predictable cost per
sample
Generally more expensive; library prepn costs
accumulate per sample; sequencing costs
accumulate per lane (into which samples
may be multiplexed)
49
Level of technical variability Higher Lower 40, 50
Sample size calculation method Standard tools for calculation Complex tradeoff between sample numbers,
read depth, and cost
34
Presence of batch effects Sometimes problematic between chips; very
problematic between different arrays; well-
developed software tools can compensate
for batch effects to some extent
Mainly during library prepn; software tools to
compensate for batch effect are evolving
51
Types of technical bias Background and cross-hybridization bias; dye
bias arising from samples labeled with
different dyes
Length bias arising from differences in
transcript lengths between genes and GC
content bias, with uneven coverage in GC-
poor or GC-rich regions
52–55
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host-parasite interactions (66–68). We aim to provide a broader overview, integrating
ﬁndings across disciplines and across host and parasite species and highlighting the
potential of the simultaneous analysis of host and parasite.
Over the 15 years since the earliest of these studies was reported, the available
technologies have evolved considerably (Fig. 2). Most studies considered in this review
used microarray technology, although there has been a recent proliferation of RNA-seq
studies. Only two reported studies conducted dual-transcriptome analyses (25, 69).
Here we synthesize the most important ﬁndings from these studies and consider their
implications under ﬁve broad categories: technological advancement, basic biology,
immune response, pathogenesis, and biomarkers. This synthesis is limited by the
heterogeneity of experimental designs, technical and analytical approaches, and or-
gans and species studied (Fig. 3), but despite this, some consistent ﬁndings and some
clear holes in current knowledge emerge.
What Have Transcriptomic Studies Taught Us about Malaria?
Technical challenges and solutions. The ﬁrst complete genome sequence of P.
falciparum was reported in 2002 (70) and was soon followed by transcriptomic studies
of parasite gene expression in vitro (71, 72) and in vivo (23). Draft genomes of rodent
malaria parasites began to be reported at the same time (73, 74), and together, these
resources opened the way for exciting analyses of host-parasite interactions in humans
and popular experimental models. Since most transcriptomic studies have the implicit
assumption that transcription and translation are tightly linked, ribosomal sequencing
has only recently conﬁrmed that this is indeed largely true for P. falciparum albeit with
some evidence of additional translational regulation (75).
There are speciﬁc technical challenges associated with transcriptomic analyses of
FIG 3 Transcriptomic host response to malaria in humans and mice. Shown is a comparison of selected features of the transcriptional host
response to malaria in humans (left) and mice (right). Pie charts indicate how frequently each tissue has been studied for each species.
Broad functional groups of genes are presented as upregulated (light red) or downregulated (light blue) in each species for uncomplicated
disease and for cerebral malaria (CM) or experimental cerebral malaria (ECM). Common functional groups between humans and mice are
marked in boldface type.
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Plasmodium species, including intrinsic properties of the parasite genomes; the mixing
of parasite and host RNAs, which accompanies parasitism; the variation in gene
expression with progression though the developmental cycle; and the inaccessibility of
parasites at certain stages of the life cycle.
The genome of P. falciparum has one of the most AT-rich compositions among all
eukaryotes (70), which has made accurate sequencing, annotation, and assembly of the
genome and transcriptome more difﬁcult. High AT content creates PCR ampliﬁcation
bias and homopolymer tracks, which can bias quantitative analyses and makes read
mapping more difﬁcult because it results in more repeats. Plasmodium genomes also
contain multigene families, which, particularly in P. falciparum, display extreme levels of
genetic variation and present challenges for probe design and sequence mapping or
assembly (19, 76). The classiﬁcation of genes within one of these multigene families
using domains that can be deﬁned by PCR has enabled speciﬁc groups of the var genes
of P. falciparum to be associated with clinical phenotypes (77). Other multigene families,
such as rif and stevor (19), have not yet been characterized in such detail, and there is
also genetic diversity in many other loci (78). Workaround solutions have been devel-
oped, such as custom arrays with probes designed to capture transcripts from multiple
different parasite strains (79), but it is difﬁcult to know how much diversity they really
capture. Highly polymorphic genes present a particular challenge for reference-based
RNA-seq analyses, and even though de novo assembly of transcripts is possible, the best
way to accurately assemble, quantify, and compare expression levels between speci-
mens is still uncertain.
Much of the Plasmodium life cycle is spent within host cells, and so another technical
challenge is separating the mixed host and parasite RNAs that occur in biological
samples. One of the ﬁrst solutions was the simultaneous capture of host and parasite
transcriptomes by using custom microarray designs with probes speciﬁc for each
species (69). Next-generation sequencing (NGS) technology allowed alternative ap-
proaches to be applied, with the potential to separate signals from host and parasite
RNAs (either physically or computationally) and then analyze them individually or in
comparison with each other. The application of custom-designed nonrandom primers
enabled the speciﬁc analysis of parasite transcripts by excluding human RNA, rRNA, and
globin mRNA at the library preparation stage (80). However, unambiguous mapping of
even relatively short reads to one species or the other has since been demonstrated to
be possible when whole-blood host and parasite mRNAs were captured by using
poly(A) selection and simultaneous sequencing (25).
In vitro parasite development can be synchronized through various treatments (81),
but in vivo, parasites may coexist at different developmental stages. Plasmodium
exhibits stage-dependent gene expression (discussed in more detail below), which can
confound the interpretation of the transcriptome obtained from analysis of mixed
stages. Several analytical approaches have been developed to try to estimate the
developmental stage of parasites, including a maximum likelihood approach using
global gene expression (82) and a more simplistic approach using single, stage-speciﬁc
marker genes (83). Despite the clear rationale for these methods to be applied, it is
notable that few transcriptomic studies of malaria have used them.
Parasite sequestration in the microvasculature is a pathognomonic feature of P.
falciparum malaria (17, 18), and the extent of sequestration is one factor that contrib-
utes to differences in developmental-stage mixtures (84). Sequestration is strongly
associated with pathogenesis, and so transcriptomic analyses of sequestered parasites
may reveal mechanisms of severe disease. However, sequestered parasites are absent
from the circulating blood and therefore are difﬁcult to access. One approach has been
to use formalin-ﬁxed parafﬁn-embedded postmortem tissue blocks from patients who
died of malaria, and these specimens enable sequestered parasite gene expression
proﬁles to be obtained from brain and other tissues (85). This potentially opens the way
for exciting dual RNA-seq studies on similar specimens (Fig. 2), which may reveal much
more about the interaction of sequestered parasites with the host vascular endothe-
lium and the tissues in which they are located.
Transcriptomic Studies of Malaria Microbiology and Molecular Biology Reviews
June 2018 Volume 82 Issue 2 e00071-17 mmbr.asm.org 9
 o
n
 M
ay 9, 2018 by SW
ETS SUBSCRIPTIO
N SERVICE
http://m
m
br.asm
.org/
D
ow
nloaded from
 
Basic biology: parasite biology. One of the most fundamental applications of
transcriptomics to parasite biology has been the use of RNA-seq to improve the
annotation of parasite reference genomes by identifying novel transcripts, verifying or
correcting gene models, and identifying splicing sites (86, 87). This has proven partic-
ularly useful for the precise annotation of the P. falciparum genome and also produced
major improvements in previously fragmented genomes of the common model rodent
malaria parasites (88). Such a comprehensive annotation is a prerequisite for any
attempt to relate quantitative gene expression to parasite biology.
Microarray and RNA-seq studies have also been fundamental for understanding the
variation in gene expression that accompanies the complex life cycle of Plasmodium
parasites and for identifying transcription factors that control its progression (71, 86, 89,
90). Throughout the intraerythrocytic cycle, there is a striking phasic variation in the
expression of the majority of parasite genes (71, 86, 91), which rations protein produc-
tion to occur only when the proteins are required. For example, genes involved in
erythrocyte invasion are expressed only in mature schizonts so that when daughter
merozoites are released into the blood, they are fully equipped to invade new red cells
(71). Despite a conserved overall pattern of phasic variation, the expression of individ-
ual homologue genes is not so highly conserved among different Plasmodium species
and shows the greatest variation at the stage of the greatest interaction with the host
cell, during early-ring-stage development (91). The development of the gametocyte
forms, required for the transmission of Plasmodium from vertebrates to mosquitoes, is
accompanied by another unique gene expression proﬁle and controlled by a master
regulator transcription factor, AP2G (89, 90).
Since gene expression is so tightly linked to the developmental stage, it is not
surprising that comparisons of gene expression levels between samples with asynchro-
nous parasite populations (as often seen in vivo) can be misleading if no consideration
is given to the composition of the mixture of parasite stages (82). However, assessment
of parasite gene expression in vivo is very important, as there may be transcriptomic
variation that is not seen under the standardized conditions used for parasite propa-
gation in vitro. One of the ﬁrst studies to attempt global gene expression analysis in vivo
identiﬁed several different patterns in parasites drawn from malaria patients (92), and
by analogy to the better-understood biology of Saccharomyces cerevisiae, these pat-
terns were related to distinct physiological states (92). These states were also related to
host factors, including cytokine proﬁles, which raised the intriguing possibility that they
may represent a parasite response to the host environment. However, a subsequent
reanalysis of these data suggested that much of the variation was due to differences in
the mixtures of developmental stages between subjects rather than large changes in
the gene expression of parasites at the same developmental stages (82).
Recently developed single-cell RNA-seq approaches offer the potential to overcome
some of the problems with bulk analyses of mixed parasite populations (90), although
the practical and technical challenges for achieving unbiased transcriptome analysis are
signiﬁcant. Most current methodologies are restricted to polyadenylated transcripts,
losing information on small noncoding RNAs and some long noncoding RNAs (93).
Transcript recovery rates can be low, even for deep sequencing (94), and the low RNA
content in small microbes can further diminish recovery (95). The decision of whether
to examine large numbers of cells at a low sequence depth or small numbers of cells
at an increased depth depends very much on the motivation for the experiment (93,
96), yet carefully designed experiments with these limitations in mind are still revealing.
For example, preliminary results suggest that even in synchronized parasite cultures,
subtle variation in the developmental stage may create an illusion of sinusoidal
patterns of gene expression during the erythrocytic developmental cycle of P. falcip-
arum, when in reality, the pattern is much more discontinuous (97).
Descriptive analyses of the distribution of parasite developmental stages in vivo
have provided useful information in their own right, allowing the timing of parasite
sequestration to be pinpointed to around 22 h after erythrocyte invasion and providing
insights into gametocyte development (98). Very-early-ring-stage gametocytes and
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mature gametocytes were detectable in blood, while the intermediate stages of
gametocyte development were not detectable, consistent with the concept that this
occurs in sites of sequestration (20).
Comparisons between Plasmodium species can give valuable insight into parasite
biology. All Plasmodium genomes sequenced to date have multigene families in the
subtelomeric regions of most of their chromosomes (70, 88, 99–104), which encode
proteins expressed close to or on the surface of iRBCs. Depending on the species, up
to 30% of the parasite genome is dedicated to these multigene families (105), sug-
gesting that they have important roles (99). One of the best-known multigene families
is the var family of P. falciparum, which encodes around 60 different copies per parasite
of P. falciparum erythrocyte membrane protein 1 (PfEMP1) variants, antigenically
diverse proteins expressed on the surface of iRBCs (19). The transcriptional control of
var expression results in antigenic variation and immune evasion (19, 106–109). var
genes are also involved in the interaction with and adhesion to host cell surfaces, such
as adhesion to the vascular endothelium (resulting in sequestration) or binding to
uninfected RBCs (a phenomenon known as rosetting), both of which are correlated with
virulence (19, 108). While the var gene family is unique to P. falciparum, the PIR
(Plasmodium interspersed repeat) multigene family can be found in every Plasmodium
genome that has been sequenced so far. This vast gene family includes large numbers
of gene loci in each species, including stevor (40 loci) and rif (180 loci) in P.
falciparum, 180 loci in P. berghei, 800 loci in P. yoelii, 200 loci in P. chabaudi, 68
loci in P. knowlesi,1,200 loci in P. cynomolgi and P. vivax,250 loci in P. malariae, and
nearly 2,000 loci in P. ovale (99, 100, 105, 110, 111).
Transcriptomic studies have revealed fascinating insights into the role of this gene
family in P. chabaudi infection. The repertoire of expression of the P. chabaudi PIR
(Pc-PIR) genes is strongly inﬂuenced by whether mice are infected by a mosquito bite
or serial blood passage, and these modes of transmission also determine parasite
virulence (112). Serial blood passage leads to the expression of a single dominant Pc-PIR
gene in blood-stage parasites and increased virulence, while mosquito transmission
seemingly reverses the constraints imposed by serial blood passage, allowing a greater
repertoire of Pc-PIR genes to be expressed, and parasites are less virulent. The mech-
anism by which this proﬁle is reset is unknown but is hypothesized to have an
epigenetic basis (112, 113). An interesting parallel is that the diversity of the array of var
genes expressed in an infected human host may also decrease as virulence increases
following serial blood passage (112, 113).
The Pc-PIR genes also play a role in the establishment of chronic or persistent
infection, which is important for parasite transmission. Comparisons of parasite tran-
scriptomes in acute and chronic P. chabaudi infections revealed the differential expres-
sion of about half of the Pc-PIR genes. Most of these genes were upregulated during the
acute phase of infection (113). Interestingly, this differential expression was not a
consequence of immune selection but rather reﬂected the expression of speciﬁc
clusters of Pc-PIR genes that were consistently associated with either acute or chronic
infection, suggesting programmed rather than selected expression and another un-
known mechanism, which will be important to delineate (113, 114).
These ﬁndings once again raise the question of whether the control of parasite gene
expression in vivo is well represented in laboratory-adapted parasites grown for many
generations in vitro, which are the basis for much of our knowledge about parasite
biology. Existing evidence (albeit from small studies) suggests that parasite gene
expression is generally well conserved between laboratory-adapted P. falciparum
strains and parasites directly sampled from naturally infected humans (115). However,
the expression of genes encoding molecules exported to the red cell surface, including
those of the rif and stevor families, appears upregulated in vivo compared to that in
laboratory strains. Among subjects with severe malaria, greater departures from the in
vitro transcriptome have been described (116), perhaps suggesting that the more
perturbed the host environment, the more the parasite must adapt its gene expression.
Adaptation of parasite gene expression to the host environment was recently demon-
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strated when infected mice were fed either low-energy or normal diets, with changes
in the parasite transcriptome leading to the identiﬁcation of the putative serine/
threonine kinase KIN as a parasite sensor of host nutritional status and a regulator of
parasite growth (117).
Controlled approaches comparing synchronous parasites from recently culture-
adapted ﬁeld isolates and long-term-laboratory-adapted strains have also conﬁrmed
variation in the expression of genes encoding parasite proteins exported to the red cell
and to its surface as well as higher expression levels of genes coding for sexual-stage
proteins in ﬁeld isolates. In a study of Kenyan parasite isolates, this differential expres-
sion appeared to be partly attributable to genetic changes, particularly copy number
variation (118). Interestingly, studies of inbred mice infected with the nonlethal parasite
P. yoelii 17X showed a considerable conservation of parasite gene expression over time
and between hosts, even among hosts with different immune statuses. The greatest
variation occurred at peak parasitemia, when there was maximal reticulocytosis, and
the parasite may require different proteins for the most efﬁcient growth in these young
RBCs (119). Taken together, these ﬁndings suggest that many variations in parasite
gene expression in vivo may be determined by the necessity for an optimal interaction
with host erythrocytes. The question of whether additional large-scale variation in gene
expression plays a causal role in severe disease in humans remains to be fully resolved.
Immune response. (i) Naturally occurring immune responses. The complex life
cycle of Plasmodium means that the immune response to malaria needs to be under-
stood as a series of responses to spatially, temporally, and antigenically distinct life
cycle stages (14) (Fig. 1). Superimposed on this, the intensity, duration, and timing of
previous infection can modulate acquired immunity (15, 21). Enormous antigenic
variation creates considerable challenges for the immune system. Although a huge
amount has been learned about immune responses to malaria in both humans and
animal models (120), most of our understanding comes from reductionist studies, and
the integrative understanding of the immune responses at a systems level remains
rudimentary.
Transcriptomic studies therefore play an important role in and are potential building
blocks for an integrated description of immune responses to malaria. It would be ideal
to obtain serial samples from all relevant tissues, starting before inoculation by a
mosquito bite, through the presymptomatic and symptomatic phases of infection, and
onwards until the time of death, resolution, or persistent infection. This may be possible
in animal models (although it has not yet been done), but human studies are often
constrained by the limited availability of any sample type other than blood and the
practical and ethical challenges of longitudinal sampling (121). Thus, we must piece
together a likely sequence of events from limited samples from humans and data from
experimental malaria infections in other species.
Insights into some of the earliest immune responses to blood-stage parasites in
humans come from controlled-infection studies, whereby malaria-naive individuals are
infected by a mosquito bite or the inoculation of blood-stage parasites and then
intensively monitored for the detection of parasites in their blood (122, 123). An early
microarray study showed that large changes in peripheral blood mononuclear cell
(PBMC) gene expression were already apparent at the time of the ﬁrst detection of
parasites on a blood ﬁlm, which for most subjects preceded the onset of symptoms
(124). These changes included the upregulation of cell surface and intracellular pattern
recognition receptors, proinﬂammatory cytokines, phagocytic and scavenger receptors,
and NADPH oxidase components, together indicating a coordinated activation of
multiple components of the innate immune response. Interferon gamma (IFN-) sig-
naling pathway, interleukin-1 (IL-1) signaling, and glycolysis pathway genes were
prominently activated early in infection, as were genes involved in antigen processing
and presentation for major histocompatibility complex class I (MHC-I) and MHC-II;
however, the upregulation of the expression of the IL-1 receptor and heat shock
protein genes was limited to subjects who developed fever (124). Looking slightly later
in infection, when previously malaria-naive subjects ﬁrst developed fever, broadly
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similar ﬁndings were observed by using RNA-seq, although the downregulation of T-
and B-lymphocyte genes was noted (125).
Gene expression proﬁles from naturally infected individuals at the time of clinical
presentation with acute uncomplicated malaria (UM) show many similarities with those
of presymptomatic experimentally induced infections (24, 25, 124–126). However, the
additional induction of genes related to interleukin-10, mitogen-activated protein
kinase activation, and Fas ligand-induced apoptosis was detectable in PBMCs of
naturally infected, symptomatic Cameroonian adults (124). Type I interferon-related
genes were highly induced by infection in comparison to healthy controls and in
comparisons of paired acute- and convalescent-phase samples from Brazilian patients
(127, 128). Comparison of whole-blood gene expression from symptomatic previously
naive individuals with that from symptomatic Malian adults showed less upregulation
of interferon responses but greater upregulation of B-cell receptor signaling in malaria-
experienced individuals (125). Prominent neutrophil-associated signatures were addi-
tionally found in whole blood from symptomatic children (24, 126). The most perplex-
ing differences observed between studies of symptomatic individuals relate to
opposing changes in MHC-, T-cell-, and B-cell-associated genes (24, 124–126). These
conﬂicting ﬁndings may represent genetic or environmental differences between the
different comparison groups, differences in parasite loads between subjects (126), or
changes in the proportions of leukocyte subpopulations in infection, the effect of which
is dependent on whether RNA is extracted from PBMCs or whole blood.
Differences between the transcriptional proﬁles seen in cases of uncomplicated and
severe malaria have been less studied. A paired comparison of 5 individuals who ﬁrst
presented with severe malaria and later returned with an episode of uncomplicated
malaria found that IFN pathway and T-cell response genes were more highly expressed
in the uncomplicated episodes than in the severe episodes (129). Although that study
did not speciﬁcally consider the association of gene expression with parasite load, other
observations (126) suggest that this difference may be largely a consequence of the
lower parasite load at presentation with uncomplicated malaria.
Since natural exposure often involves repeated Plasmodium infections, transcrip-
tomic approaches have been used to understand the consequences that one or more
episodes of malaria may have on subsequent responses to Plasmodium or other
pathogens. Comparison of PBMC transcriptomes of Malian children 7 days after treat-
ment for the ﬁrst acute episode of the malaria season with transcriptomes just before
the onset of the malaria season revealed the downregulation of inﬂammatory genes
but the upregulation of genes expected to facilitate microbial killing and the activation
of adaptive immunity (130). Stimulation of these PBMCs with infected RBCs also
resulted in lower expression levels of inﬂammatory genes but higher expression levels
of microbial killing and adaptive immunity genes in the samples from 7 days after
infection. Those ﬁndings suggest that one episode of infection might be able to
program a more advantageous response to subsequent infection. However, there is
also abundant evidence that acquisition of immunity is inefﬁcient, and repeated
malaria exposure impairs heterologous immune responses and increases susceptibility
to other infections (131, 132). Dysfunctional atypical memory B-cell populations have
been described for other infections associated with poor antibody production (133),
and transcriptome analysis has been central to deﬁning atypical memory B-cell popu-
lations related to chronic malaria infections, which are defective in immunoglobulin
production and denoted by the surface expression of FCRL5 (134, 135).
There are few data on the evolution of changes in the blood transcriptome with the
progression of infection in animal malaria models, although data available for P.
chabaudi infections suggest that there are considerable overlaps with the human blood
transcriptome in uncomplicated pediatric malaria (126, 136, 137) (Fig. 3). Pathway-level
similarities include the upregulation of IFN response, antigen presentation, and
proteasome-related genes; the downregulation of B-cell genes; and gene-level overlap
of the upregulation of Fc receptors. However, T-cell signaling was upregulated in
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mouse whole blood, in contrast to the lower expression levels in human whole blood
reported by those same authors (126).
In a different rodent infection, P. berghei ANKA, the immune responses in liver,
spleen, lungs, and brain were monitored at sequential time points (69). Although that
study primarily aimed to investigate the pathogenesis of experimental cerebral malaria
(ECM), the sequential immune response over time is noteworthy because it varied by
organ and by mouse species. Overall, there were many similarities to the human
immune response genes induced by malaria, particularly in spleen, liver, and lung,
where Toll-like receptor (TLRs), proinﬂammatory cytokine, interferon-inducible, and
complement-related genes were induced. Unfortunately, that study did not include
blood transcriptome data, which might have allowed a better comparison with human
data and inference of changes in blood gene expression that may arise from the
migration of cells to and from different organs.
The accessibility of fresh organs from mice permits more-reﬁned transcriptomic
analyses on speciﬁc cell populations isolated from these organs, avoiding confounding
due to changes in cell populations within a whole organ or blood. Splenic cells have
been the primary focus of such analyses, since the spleen is a major site of interaction
between parasites and innate and adaptive immune cells, which control human and
rodent malaria infections (138). For example, puriﬁed CD11c splenic dendritic cells
(DCs) were examined at different time points during P. yoelii 17XNL-infected BALB/c
mice to resolve a controversy surrounding their function in malaria (139). At the time
of that study, opposing roles had been proposed, with DCs on the one hand enhancing
innate immune responses and initiating adaptive immune responses (140) and on the
other hand mediating the immunosuppressive effects of the parasite product hemo-
zoin (141). Transcriptomic analyses revealed several distinct patterns of gene expres-
sion over time, with many immune-related genes showing sustained levels of tran-
scription at early and late time points during infection but a notable smaller group
showing differential regulation between time points (139). Perhaps important to un-
derstanding the controversy around DC function, expression levels of il-10 were higher
and expression levels of il-6, il-12, and ifng were lower later during infection. Genes
involved in the cell cycle, glycolysis, and purine metabolism were also extensively
modulated by P. yoelii infection, in contrast to previously described “common” DC
maturation signatures, suggesting that DC behavior in malaria may not easily be
inferred from that observed in other situations (139).
Analyses of puriﬁed splenic CD4 T cells have also contributed to understanding their
role in malaria, this time in the lethal P. berghei ANKA model (142). In this model, CD4
T cells enhance pathogenicity and are ineffective at providing T-cell help to constrain
the parasite load. Their early transcriptional response to infection was dominated by
interferon gamma and, unexpectedly, type I interferon response genes, which led to
functional studies demonstrating that type I interferon was responsible for suppressed
CD4 T-cell function (142). An even deeper understanding of splenic CD4 T-cell biology
followed, using single-cell isolation and RNA-seq combined with fate mapping to
determine how CD4 T-cell clones differentiate into either T helper 1 or T follicular helper
cells (143). Cell cycle and glycolysis genes, a recurring feature in analyses of splenic
tissue (139, 144, 145), were upregulated in these cells around the time of fate deter-
mination at day 4 of P. chabaudi infection, and subsequent fate was determined by
interactions with B cells or monocytes, which favored T follicular helper or T helper 1
development, respectively (143). Undoubtedly, cell fate mapping and single-cell se-
quencing will add further essential detail and complexity to our understanding of
malaria immunology in the future.
(ii) Vaccine-induced immune responses. Transcriptomic approaches have yielded
particular success in identifying vaccine-induced protective immune responses for viral
infections such as yellow fever and inﬂuenza (146, 147), catalyzing the development of
the new discipline of systems vaccinology (148, 149). However, the development of a
protective malaria vaccine has been an arduous process because a vaccine has to
perform considerably better than naturally induced immunity, and until a partially
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protective vaccine became available, it was not possible to begin identifying correlates
of vaccine protection (14). Various strategies, ranging from intravenous whole attenu-
ated sporozoites to recombinant proteins and DNA-based vaccines, have been evalu-
ated in attempts to target single or multiple parasite life cycle stages (reviewed in
references 14, 150, and 151).
To date, the only vaccine to have achieved licensure and enter into pilot imple-
mentation in countries where malaria is endemic is RTS,S/AS01 (150, 152). This vaccine
has demonstrated only modest efﬁcacy and durability in clinical trials in African
children, but it has the potential to make a substantial public health impact (153–156).
RTS,S/AS01 is a preerythrocytic vaccine, so when effective, it either prevents or delays
the development of blood-stage parasites and clinical disease (14, 150). The imperfect
protection afforded by RTS,S has allowed transcriptomic studies of unprotected and
protected individuals to be undertaken to characterize vaccine responses, which pre-
dict subsequent protection against experimental challenge. In peripheral blood mono-
nuclear cells, plasmablast-associated transcriptional signatures, cell cycle genes, and
type I interferon genes correlated positively with immunogenicity (antibody titers to
circumsporozoite protein [CSP]) and vaccine-induced protection, while natural killer
(NK) cell genes were negatively correlated with both outcomes (157, 158). Looking at
the role of the genes by functional enrichment, immunoproteasome, cell cycle, and
apoptosis functions were associated with protection (158), and more-focused analyses
have highlighted that vaccine-induced interferon signaling may also predict protection
(159). Decreases in this response signature shortly after the ﬁnal vaccination were
associated with a lack of protection (160).
While RTS,S is the most advanced vaccine, it is not the only preerythrocytic vaccine
to be developed, and transcriptomic correlates of protection for RTS,S might be
compared with those induced by other vaccines in order to ﬁnd universal correlates of
protection. In a schedule of priming with an adenovirus-vectored vaccine and boosting
with two doses of RTS,S/AS01, a strategy designed to elicit better CD8 T-cell responses,
transcriptional correlates of protection were not identical to those of RTS,S/AS01 alone
(157). In the prime-boost approach, innate responses to the vaccine appeared more
important, with TLR signaling, dendritic cell, and antigen presentation gene expressions
all correlating with protection. The most consistent common feature between this
regimen and RTS,S/AS01 alone was a negative association between protection and NK
cell gene expression (157). However, these vaccine regimens also produced different
immunological correlates of protection, with polyfunctional CD4 T cells rather than
anti-CSP antibodies emerging as being the most important for the prime-boost regi-
men despite similar protective efﬁcacies. Ex vivo restimulation of samples from two
other studies with the vaccine antigen, using either two doses of RTS,S followed by
modiﬁed vaccinia virus Ankara (MVA)-vectored CSP or two doses of DNA multiple-
epitope thrombospondin-related adhesive protein (ME-TRAP) followed by MVA-
vectored ME-TRAP, showed that the small number of protected subjects were charac-
terized by the upregulation of interferon-induced and antigen presentation genes and
the downregulation of hematopoietic stem cell and myeloid cell genes (161). Despite
some common themes in protection-associated gene signatures from those studies,
the ideal response to provide sterile protection against preerythrocytic parasite stages
in humans remains to be characterized.
(iii) Gene expression proﬁles associated with asymptomatic infection. In countries
where malaria is endemic, it is common for individuals to have asymptomatic para-
sitemia (11, 12). The likelihood of an infection being asymptomatic increases with age
(12) and decreases with parasite load (27), but many believe that this must also involve
the active regulation of the immune response, since parasite loads tolerated under
high-transmission intensity are much higher than those causing fever under low-
transmission intensity (162). It is therefore intriguing that no signiﬁcant transcriptomic
response to asymptomatic infection was detected by RNA-seq despite comparing
paired samples prior to infection with those during infection in Malian adults albeit with
only 5 subjects per group (125).
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It is tempting to speculate that this may indicate that none of these individuals had
reached sufﬁcient parasitemia to trigger a response and that the set points for such a
response may differ between malaria-experienced and previously naive individuals.
This concept may be supported by data from a recent study comparing the transcrip-
tional responses of asymptomatic adolescent men from two sympatric ethnic groups in
Burkina Faso with similar peripheral blood parasite densities (163). Comparison of
puriﬁed monocyte transcriptomes between 7 uninfected and 2 infected individuals of
the Fulani tribe showed dramatic differences in gene expression, whereas the same
comparison for individuals of the Mossi tribe showed negligible differences. Fulani are
well known to have relative protection from malaria (164), and the authors of that study
speculated that these results might indicate an immune response that is more poised
for activity upon infection in the Fulani than in the Mossi. Further work in larger studies
restricted to individuals with persistent asymptomatic infection will be important to
investigate this issue further.
Taking a different approach, a longitudinal study identiﬁed a V2 subset of  T
cells as being reduced following chronic malaria exposure, and their gene expression
was investigated (165). Interestingly, their basal expression levels of numerous immu-
noregulatory genes were found to be increased, and their transcriptional inﬂammatory
response to infected RBC stimulation was diminished, concordant with their association
with a diminished likelihood of symptoms upon infection. This suggests that the
infection-induced attenuation of this cell population may help to explain why repeat-
edly exposed individuals become less likely to develop symptoms.
(iv) Effect of host immunity on parasite gene expression. To date, relatively little
is known about how preexisting host immunity (naturally acquired or vaccine induced)
alters parasite behavior. Transcriptomic analyses, particularly dual RNA-seq of host and
parasite, could provide insights into this question. However, some surprising ﬁndings
have arisen from studying the more fundamental question of whether the presence or
absence of speciﬁc components of host immunity alters parasite gene expression. A
common assumption has been that the expression of different members of parasite
variable gene families (such as PIR genes) enables immune evasion and is at least partly
determined by immune selection. For the Pc-PIR genes of P. chabaudi, this appears not
to be the case. Transcriptomic comparisons of parasite gene expression levels in mice
with acute and chronic infections demonstrated that the establishment of chronic
infection was indeed associated with a clear shift in Pc-PIR gene expression, but this was
not inﬂuenced by the removal of immune selection in mice without T cells (TCR/
mice) or without B cells and antibodies (MT mice) (113). This ﬁnding conﬂicts
somewhat with human data that suggest that var gene expression is affected by
preexisting humoral immunity (166).
Pathogenesis. Malaria typically causes fevers, headache, myalgia, rigors, cough, and
abdominal pain, features which are similar to those of many other systemic infections
(11, 12). Laboratory tests often show anemia, thrombocytopenia, and increased levels
of acute-phase response proteins (12, 18). Features associated with an increased risk of
death include coma, renal failure, metabolic acidosis, hypoglycemia, respiratory dis-
tress, and severe anemia (167, 168). The pathogenesis of the clinical and laboratory
features of malaria is incompletely understood, and this is especially so for the
progression from uncomplicated to severe malaria (13). Although transcriptomic ap-
proaches have the ability to broaden our understanding of the changes that occur in
the host and the parasite during infection, relatively few studies have sought to
associate gene expression with speciﬁc features of human disease (24, 25, 124, 169–
171). In contrast, transcriptomic studies with animal models have frequently been used
to try to provide an understanding of the pathogenesis of severe malaria. However, the
interpretation of the results generated in these models is dependent on understanding
both the relevance of the model to human disease and the experimental design, most
importantly the severe and nonsevere comparison groups.
The most common models use inbred strains of mice of speciﬁed ages and sexes.
Unlike natural malaria infections in humans, the outcome of these models tends to be
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extremely consistent for any given combination of parasite and mouse strain. For
example, the P. berghei ANKA strain causes a neurological syndrome described as ECM
(172) in C57BL/6 and CBA mice but does not cause ECM in BALB/c mice (173). The
closely related strains P. berghei K173 and P. berghei NK65 do not usually cause ECM in
any of these mouse strains (172). Investigators have generally taken one or more
approaches to identify gene expression associated with severe disease: (i) comparison
of susceptible and resistant mouse strains infected with the same parasite strain (69,
173–177); (ii) comparison of the same mouse strain infected with different parasite
strains (137, 178); (iii) time course analyses to identify differences in gene expression
occurring before and after the onset of severe disease (69, 126, 136, 144, 175, 177, 179);
and (iv) comparison of rare, less severely affected mice with their more severely
affected counterparts of the same strain infected with the same parasite for the same
duration (136, 176). All of these approaches potentially have limitations because it is
difﬁcult to disentangle expression differences associated with the genetic background
from those causing severe malaria. Furthermore, features that are critical for valid
comparisons in models with different mouse or parasite strains, such as temporal
changes in parasitemia or total body parasite load in individual mice, have been
inconsistently reported. Despite these limitations, common features emerge from
transcriptomic studies using rodent models regardless of the experimental ap-
proach (Fig. 3).
Unfortunately, studies of pathogenesis in humans and animal models have often
been conducted in relative isolation, and the relevance of animal models, such as ECM,
to human disease is often debated because of differences in key histopathological
features, such as parasite sequestration (172, 180). Transcriptomic studies have the
potential to allow global comparisons of host and parasite gene expression between
these models and human specimens, but this has not yet been done in any formal way.
There are no studies to date comparing human gene expression from organs such as
brain or lung in severe and uncomplicated malaria cases (Fig. 3). In contrast, relatively
few animal studies have investigated gene expression in blood (126, 136, 137, 173), and
the majority of those studies focused on brain and spleen gene expression. Thus,
synthesis of ﬁndings in rodent models with those in humans is challenging (Fig. 3).
(i) Cerebral malaria and experimental cerebral malaria. The pathogenesis of
human cerebral malaria (CM) has been extensively debated because it is currently
impossible to prove the dependency of the syndrome on any speciﬁc pathogenic
mechanism. In contrast to the widely used P. berghei ANKA C57BL/6 ECMmodel, human
CM may not even be a single entity but may have several pathological subtypes
(181–184). The ﬁrst of these subtypes is not CM at all but “false CM,” with coma being
due to another cause (infectious or noninfectious) in the presence of incidental
parasitemia (181). In resource-poor settings, it is difﬁcult to exclude all other possible
causes of coma, and so they may be misclassiﬁed as CM. A relatively common and
speciﬁc feature of CM that is not present in false CM is malarial retinopathy, which
colocalizes with the sequestration of parasites in the retinal blood vessels (181, 185).
This has been used to deﬁne children with true CM, but it has become apparent that
coma in some children without retinopathy is also at least partly caused by malaria
(182, 183, 186).
(a) Host response. Few studies have compared the human or mouse blood transcrip-
tomes between CM and uncomplicated malaria (129, 170, 171) or between severe
malaria phenotypes (187). In Malawian children initially treated for CM and subse-
quently reattending with an uncomplicated malaria episode, paired analyses of whole
blood showed a striking upregulation of type I interferon-associated gene expression at
presentation with uncomplicated malaria compared to the episode of severe malaria
(129). Differential type I interferon responses were also a feature detected in a larger
study comparing Malawian children with retinopathy-positive and -negative CM, along
with a signiﬁcant enrichment of cell adhesion and extracellular matrix pathways and
numerous neutrophil-related transcripts being upregulated in the retinopathy-positive
subjects (187). There was also an enrichment of pathways related to coagulation,
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platelet activation, and cytokine signaling (187), consistent with the well-described
coagulopathy and inﬂammation that accompany CM (188, 189). Supporting the rele-
vance of the transcriptomic ﬁndings, concentrations of neutrophil primary granule
proteins (elastase and myeloperoxidase), tumor necrosis factor, monocyte chemotactic
protein 1, and interleukin-10 were higher in plasma of retinopathy-positive subjects,
whereas the concentration of IFN-2 (a type I interferon) in plasma was higher in
individuals with retinopathy-negative CM (187).
Using more-relaxed deﬁnitions of cerebral symptoms, a study in Mali that included
5 children with prostration or coma found higher expression levels of complement,
Toll-like receptor, and cytotoxic-T-cell genes than those in 5 children with uncompli-
cated malaria (171). Many of these ﬁndings parallel those for the blood transcriptome
in ECM, obtained from comparisons of susceptible and resistant mouse strains infected
with P. berghei ANKA (173) (Fig. 3). Common differentially expressed genes in ECM
include the downregulation of those associated with erythropoiesis, cell surface gly-
cosylation, ubiquitination, MHC-II, platelet-related, clotting-related, and plasmacytoid
dendritic cell-related genes (many involved in type I interferon signaling) in ECM (173).
In contrast, there was an upregulation of natural killer cell- and cytotoxic-T-cell-related
genes, the latter of which is consistent with the known dependency of ECM on CD8 T
cells (173). However, changes in neutrophil gene expression signatures were not seen
in ECM (173). A different perspective comes from a recent analysis of human PBMCs
rather than whole blood, where comparison of genes associated with other neurode-
generative diseases between 7 children with CM and 8 with uncomplicated malaria
suggested that protein aggregation pathways may be activated and important in CM
(170).
In contrast to the limited studies on blood, multiple transcriptomic analyses of
mouse brain tissue have been conducted and have yielded a fairly consistent picture of
gene expression associated with ECM (69, 144, 174, 175, 177–179) despite the variety
of experimental approaches discussed above. Although the brain parenchyma makes
up the majority of specimens for gene expression analysis, it is composed of multiple
cell populations, and additional cell types may actively or passively become enriched in
the blood vessels and parenchyma during infection. Few studies speciﬁed whether
brains were perfused prior to RNA extraction, but this method of ﬂushing out nonad-
herent cells from the vasculature could result in substantial differences in gene expres-
sion due to the removal of intravascular leukocytes and immature RBCs. As evidence of
this, several studies found transcriptional signatures of suppressed erythropoiesis (144,
176, 179), which likely reﬂects analyses of cells within the brain vasculature and mirrors
ﬁndings in peripheral blood (173). The clearest consistent ﬁnding was the association
of immune response and defense pathways with ECM (69, 144, 174–178). Speciﬁcally,
genes associated with both type I and type II interferon signaling were enriched and
upregulated in ECM versus comparators (69, 144, 174, 175, 178, 179). Genes associated
with T-cell activation and granzyme were also enriched in several studies, consistent
with their known role in ECM (144, 174–178, 190).
In some comparisons, an upregulation of type I interferon responses was found to
precede the onset of cerebral pathology (69, 144), which is possibly related to sequen-
tial activation in different cell types, because isolated microglial cells showed prominent
type I interferon gene expression proﬁles only after the onset of ECM (191). The
prominence of type I interferon responses in those studies, associated with decreases
in the levels type I interferon response genes in peripheral blood (173), leads us to
suggest that there is likely a redistribution of cells producing type I interferon and/or
a sequential pattern of upregulation followed by downregulation of type I interferon
signaling, which varies in its timing by organ, progressing from peripheral blood to the
brain vasculature to the brain parenchyma.
Beyond implicating immunopathological mechanisms initiating ECM, brain tran-
scriptomes have also revealed possible explanations for neurological dysfunction. The
increased expression and activation of apoptosis pathways were observed in several
studies, along with a variety of cellular stress response pathways (175–178). However,
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pathological studies of ECM suggest that apoptosis is unlikely to be a major cause of
ECM because it is an infrequent event, rare in parenchymal cells, and when occurring
in vascular endothelial cells, it is not associated with adjacent edema or hemorrhage
(180). One time course comparison of ECM-susceptible and -resistant mice reported
evidence for an early downregulation of metabolic processes, such as glycolysis, in the
brains of susceptible mice, which may plausibly contribute to reversible neurological
dysfunction (177). However, many of the changes in gene expression associated with
ECM may represent upstream events or noncausal associations, and it is possible that
transcriptional changes actually play little role in the ﬁnal neurological manifestations.
A comparison of brains of wild-type C57BL/6 mice with ECM to those of resistant CD8
T-cell-deﬁcient and perforin-deﬁcient mice revealed smaller sets of differentially ex-
pressed genes than in a comparison with resistant BALB/c mice (176). In fact, it was
striking that only 9 genes differed between perforin-deﬁcient mice and wild-type mice
with ECM, yet the perforin-deﬁcient mice did not develop ECM, suggesting that the
expression levels of very few genes need to change to produce the ﬁnal neurological
syndrome (176).
The spleen plays important roles in the innate clearance of parasites, the adaptive
immune response, and erythropoiesis (in mice) (22, 138). Splenic gene expression has
been investigated in both ECM and non-ECM severe rodent malaria models. Consistent
with ﬁndings for other tissues, erythropoiesis genes were suppressed as ECM pro-
gressed (144) and were also suppressed in other lethal infections (discussed below).
Metabolic pathway changes in the spleen accompanied the progression of infection,
such as increased expression levels of glycolytic enzymes detected in whole spleen
(144) and puriﬁed splenic CD11c dendritic cells (139), which may well represent
metabolic switches necessary for immune cell proliferation and function. The induction
of interferon-responsive genes in the spleen was found over the course of P. berghei
ANKA infection in ECM-susceptible mice (144) but was greater at both baseline and late
in infection in ECM-resistant mice, adding further complexity to understanding the
roles of interferons in promoting or preventing ECM (69).
In an attempt to achieve a more integrated understanding, sequential changes in
gene expression in spleen, brain, lung, and liver were examined in comparisons
between ECM-susceptible and -resistant mice (69). Large groups of immune response
genes showed consistent differences between mouse strains at all time points, but
there were also clusters of immune response genes that became differentially
expressed in different organs at different times, starting with the liver and later with the
spleen and lungs. These temporally differing clusters may reﬂect the ability of the
ECM-resistant BALB/c mice to mount earlier organ-speciﬁc responses to the parasites,
but it remains unclear how this might prevent subsequent damaging responses in the
brain (69).
(b) Parasite factors. Attempts to link parasite gene expression to the pathogenesis of
CM have supported a link between the expression of speciﬁc var genes and severity but
beyond this have been rather inconclusive. Targeted analysis of the var transcriptome
revealed that severe malaria (both CM and severe anemia) was associated with high
expression levels of var genes encoding PfEMP1 variants with cysteine-rich interdomain
regions predicted to bind to the endothelial protein C receptor (192), consistent with
previous functional analyses highlighting the importance of this interaction in severe
malaria (193, 194).
Analysis of P. falciparum isolates from 58 Malawian CM patients revealed consider-
able variation in parasite transcriptomes between subjects (116), with some showing
marked departures from proﬁles observed in vitro (92). The strongest determinant of
differences in these proﬁles was peripheral blood parasitemia (116). Subsequent com-
bination of those data with additional gene expression data from subjects with
uncomplicated malaria suggested that CM-associated parasites might show increased
expression levels of genes that modify cytoadhesion and the rigidity of infected
erythrocytes, exported proteins, and erythrocyte invasion proteins (98). Although
highly plausible, that same study also highlighted the confounding effect of variation
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in the parasite developmental stage (98), and a smaller study that directly addressed
this issue did not ﬁnd any signiﬁcant residual differences between groups with severe
(including CM) and uncomplicated malaria (82).
Parasite gene expression in ECM has also been examined by using custom microar-
rays, but at that time, functional annotation of the P. berghei ANKA genome was rather
limited (69). Nevertheless, organ-speciﬁc differences in parasite gene expression were
detected, with the lung having the greatest detectable parasite gene expression,
enriched in heat shock, ribosomal protein, and proteasome genes (69). Interpretation of
such ﬁndings is challenging because differences may simply reﬂect differences in the
distributions of parasite developmental stages associated with different organs, and a
more reﬁned analysis would be required to identify true differences in parasite gene
expression in different tissues and to relate these differences to the already complex
patterns of organ-speciﬁc host gene expression.
(ii) Other malaria phenotypes. CM is the most studied severe malaria phenotype,
but other life-threatening manifestations include severe anemia and respiratory distress
(167). Respiratory distress is usually due to acidosis in children and reﬂects compen-
satory hyperventilation to raise the blood pH by the exhalation of more carbon dioxide
(13). In adults, malaria-associated respiratory distress often represents true lung pathol-
ogy with a picture similar to those of acute lung injury and acute respiratory distress
syndrome (12). Severe anemia is probably the most common severe manifestation of
malaria in very-high-transmission settings (13). If prompt blood transfusion and anti-
malarial treatment are available, the mortality rate can be low (195). Malaria in preg-
nancy is a special case that can result in severe disease manifestations in the mother
but also placental dysfunction and adverse outcomes for the fetus ranging from
abortion or stillbirth to growth retardation and premature birth (196). Non-ECM lethal
animal models mostly lead to death through a combination of severe anemia and other
organ dysfunction, which may include lung and liver pathology (197).
(a) Host response. Fever is one of the key clinical features of malaria, but there is great
variation in the temperatures at the time of clinical presentation among individuals
infected with the same parasite species, likely reﬂecting the parasite load, synchronicity,
and how recently iRBCs have ruptured and released parasite material (198). It is curious
that body temperature has been the most common clinical variable analyzed for an
association with global gene expression in humans, because it is likely to be con-
founded by many factors and is not useful for the prediction of clinical outcome. In
whole blood, the expression of neutrophil-related (24) and lysosome-related (25) genes
has been signiﬁcantly associated with body temperature in acute malaria, while in
PBMCs, heat shock proteins, interleukin-8 (a chemokine that promotes neutrophil
chemotaxis), and interleukin-1 were signiﬁcantly associated (124, 169). Unfortunately,
no statistically signiﬁcant associations of gene expression with the severity of anemia
or with platelet counts have been identiﬁed in the few small studies examining these
more important laboratory markers of pathogenesis (24, 169). The potential for the
correlation of gene expression with clinical and laboratory features of malaria patho-
genesis has not yet been fully exploited.
Pathogenicity-associated whole-blood host transcriptional proﬁles in mice have
predominantly been assessed during P. chabaudi infections (136, 137). Comparisons
between virulent CB strain and less virulent AS strain infections showed clusters of
differentially expressed genes that had functional associations with platelet aggrega-
tion in dying mice and a more pronounced anemia signature and a neutrophil-
dominated lung inﬂammation signature in CB-infected mice (137). Infection with the P.
chabaudi AJ strain alone was analyzed in an innovative time course study (136) using
gene expression to describe trajectories from health to illness and thence to either
recovery or death. Intriguingly, in this model, the nadir of health in mice was preceded
by NK cell gene expression but also showed transcriptional evidence of depressed
erythropoiesis. A similar sequence of gene expression dynamics was inferred in humans
by mapping sequential mouse data onto patterns of gene expression from a cross-
sectional study of subjects with uncomplicated malaria (126). This novel approach may
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represent an important advance because it is almost impossible to examine sequential
gene expression in humans with untreated symptomatic malaria, but consequently,
robust validation is also challenging.
In other mouse models, analysis of the spleen transcriptome revealed reduced
expression levels of genes associated with erythropoiesis at equivalent parasitemias in
lethal P. berghei N67C infection compared with nonlethal P. berghei N67 infection (199)
and the relative suppression of erythropoiesis for the severity of parasitemia in lethal P.
yoelii 17XL infection versus nonlethal P. yoelii 17X infection (145). Type I interferons
were particularly upregulated in spleen and shown to contribute to an enhanced
control of parasitemia in nonlethal P. berghei N67 versus P. berghei N67C infection (199).
However, this is not necessarily a universal mechanism for protection from severe
disease. In a rat model using P. berghei ANKA (which does not cause ECM in this host),
young rats failed to control parasitemia and died, while older rats controlled para-
sitemia, dependent on the differential expression of a small set of genes in the spleen,
mostly related to T-cell function (200).
Individuals living in areas where malaria transmission is common develop immunity
through repeated infection, and many become clinically immune by childbearing age
(21, 196). However, women undergoing pregnancy for the ﬁrst time are susceptible to
infection by P. falciparum parasites expressing distinct variant surface antigens that
enable them to be sequestered in the placenta (196). This is thought to be because
chondroitin sulfate A (CSA) is expressed in the (placental) vasculature only during
pregnancy, and so parasites that are able to bind to CSA do not have a selective
advantage at any other time in life and have never been the target of the host immune
response (19, 196). In pregnancy, parasites expressing a CSA-binding variant of PfEMP1
can be sequestered in the placenta, avoid splenic clearance, and establish infection in
an otherwise partially immune individual, and several transcriptomic studies support
the concept that there is speciﬁcally increased expression levels of var2csa in parasites
isolated from the placenta (80, 201, 202).
Human gene expression in the placentas of malaria-infected women showed con-
siderable perturbation, with distinct patterns related to both infection status and the
presence or absence of histological inﬂammation (203). B-cell- and macrophage-related
genes were particularly enriched, including CXCL13, a macrophage-derived B-cell
chemokine. Transcriptomic ﬁndings, combined with additional reverse transcription-
PCR (RT-PCR) and immunohistochemical analyses, led the authors of that study to
speculate that macrophage CXCL13 drives B-cell recruitment to the placenta, antibody
production, and further antibody-mediated activation of inﬂammation, in a pattern
suggestive of lymphoid neogenesis (203). A subset of these differentially expressed
immune response genes was negatively correlated with birth weight (203). This is a
particularly important ﬁnding since low infant birth weight is a major risk factor for
infant mortality (204).
(b) Parasite factors. There are few studies examining parasite transcriptomes in asso-
ciation with the pathogenesis of noncerebral severe malaria. Dual RNA-seq revealed
126 parasite genes signiﬁcantly associated with high fever, with the strongest associ-
ation occurring with PF3D7_0500900 (serine/threonine protein kinase, FIKK family
[FIKK5]) (25). However, those results should be interpreted with caution since fever
spikes are thought to be related to parasite egress from RBCs, which is dependent on
the distribution of the developmental stages of the parasites, which in turn is the
greatest determinant of parasite gene expression. FIKK5, for example, shows substantial
variation in expression across the developmental cycle in vitro (86). That same study
identiﬁed 234 parasite genes associated with the proportion of whole-blood reads
mapped to the parasite (a proxy for circulating parasite density), but these genes were
poorly annotated at the functional level, making it difﬁcult to understand how they may
be related to the parasite load (25).
Comparison of parasite gene expression levels has been performed with a small
number of adults with noncerebral severe malaria (predominantly subjects with
renal impairment) versus those with uncomplicated malaria by using a custom
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microarray designed to identify a broader repertoire of genes from variant gene
families of parasites (205). Given the small size of that study, it was surprising that
380 genes were identiﬁed as being differentially expressed, with a notable down-
regulation of genes associated with host cell entry in severe malaria as well as
enrichment for metabolic processes and RNA splicing and the differential expres-
sion of a range of variant surface antigens (205). The generalizability of these
ﬁndings remains to be determined.
In pregnancy-associated malaria, transcriptomic analyses of parasites from placental
malaria have found modest numbers of differentially expressed genes other than
var2csa, many of which are thought to be exported into erythrocytes but do not have
well-deﬁned functions (80, 201, 202). This suggests that beyond the importance of
var2csa, additional mechanisms of the host-parasite interaction may also play a role in
susceptibility to malaria in pregnancy.
(c) Host-pathogen interaction. The association between host gene expression and
parasite load is of interest because the parasite load is a determinant of severity and
because restriction of the parasite load would indicate protection. Several studies of
different patient groups have related host gene expression to parasitemia and
found fairly consistent associations with the upregulation of neutrophil-, interferon-,
phagocytosis-, complement-, and heme degradation-related genes (24, 25, 126). As-
sessment of the association of host gene expression with PfHRP2 concentrations, as a
proxy for the total body parasite load, has not yet been done. The whole-body parasite
load (which includes both circulating and sequestered parasites) is generally a much
better predictor of outcome than circulating parasitemia (18, 26–30), and so this
analysis will be important in future studies.
A direct correlation of host and parasite gene expressions was possible in only one
study to date, which used dual RNA-seq to analyze whole blood from uncomplicated
P. falciparum malaria cases in Indonesia (25). Host innate immune response genes were
negatively correlated with parasite metabolic process genes, perhaps suggesting a
direct impact of the host response on the restraint of parasite metabolism. However,
most of the correlations between human and parasite gene expressions were positive,
and among these genes, the most notable were human transcription factor genes
positively correlated with parasite translational regulation (25). Despite caveats about a
confounding effect of the parasite developmental stage in that study, it is intriguing to
speculate that those observations may indicate a reciprocal regulation of fundamental
biological processes between the host and parasite.
Biomarkers. Identifying reliable biomarkers can improve diagnosis and the predic-
tion of outcomes of infectious diseases. This is particularly important for malaria
because while some individuals living in high-transmission settings will have para-
sitemia, which is not the cause of their illness, others will deﬁnitely have malaria but
despite antimalarial treatment may develop severe disease, and others will have
coinfections with malaria and bacterial pathogens, both of which require treatment (11,
27, 28, 132). Identifying these groups could stratify clinical care as well as studies of
immunology, pathogenesis, and treatment. Biomarkers that can predict outcomes in
animal models have the potential to improve the power of these models and to beneﬁt
the welfare of the animals by allowing accurate sample size calculations and the use of
less-severe endpoints. Given the complexity of malaria pathogenesis, biomarker dis-
covery may provide more than just a disease indicator but also greater insight into the
cellular responses and physiology of the host and the pathogen. Increasingly
rigorous methodology is now being applied to biomarker discovery, such as
standards for reporting of diagnostic accuracy (STARD) (206), and transparent
reporting of a multivariable prediction model for individual prognosis or diagnosis
(TRIPOD) (207). Validation is required with multiple independent data sets along
with standardized reporting of how well the biomarker predicts the outcome of
interest. Most transcriptomic biomarker discovery studies of malaria have not met
this standard of evidence; nonetheless, they suggest that robust biomarkers might
be found in the future.
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(i) Diagnosis of malaria. Since we already have good tools to detect Plasmodium
using microscopy, point-of-care antigen tests, and even PCR-based parasite detection
(11), the utility of transcriptomics for the diagnosis of malaria may not be obvious. Gene
expression signatures can be derived to distinguish diseases that have similar clinical
presentations, such as distinguishing bacterial from viral infection (208) or tuberculosis
from nontuberculous infection (209), demonstrating a proof of principle that each
disease has a unique transcriptional signature that might form the basis of a rapid test
to guide initial clinical management (210, 211). In a country where malaria is endemic,
any such test would need to be able to distinguish malaria from other febrile illnesses,
and so a gene expression signature of malaria would be essential. One of the ﬁrst
transcriptomic studies of malaria suggested that this would be feasible because unsu-
pervised clustering was able to largely separate febrile malaria from other acute febrile
illness (24). Clusters were particularly separated based on neutrophil-related genes and
erythroid-related genes; however, modern variable selection methods and testing with
an external validation data set would be needed to develop a sufﬁciently small,
sensitive, and speciﬁc gene expression signature for diagnostic use.
(ii) Predictors of severity or death. The majority of transcriptomic studies attempt-
ing to identify biomarkers of severe outcomes have been conducted with animal
models rather than humans. In a comparison of gene expression patterns in mouse
brains from four different strains, 31 genes were found to distinguish ECM susceptibility
from resistance regardless of the mouse strain (174). The utility of gene expression
biomarkers in brain tissue is limited, since this tissue cannot easily be sampled without
killing mice, but it may provide a more reﬁned experimental endpoint that does not
require mice to develop end-stage ECM. Gene expression biomarkers in peripheral
blood are arguably more useful, and putative examples have been identiﬁed from a
comparison of the whole-blood transcriptomes of ECM-resistant and ECM-susceptible
mice (173). Of a large number of differentially expressed genes detected by microarray
analysis, a smaller number was conﬁrmed by RT-PCR, and several of these genes (c1qb,
DnaJC15, and tk1) were different enough between groups to be considered candidate
biomarkers. C1Q was also identiﬁed as a putative biomarker of severe human malaria
in a pilot study of 10 Malian children (171). Seven other candidate markers were all
related to the immune response, including TLR genes.
Biomarker discovery for diagnosis or prognosis is not restricted to host gene
expression only. Potential parasite biomarkers in humans have been investigated by
transcriptomic proﬁling of parasites taken from children with CM, uncomplicated
malaria, and asymptomatic malaria (212). Among them, only the comparison between
CM and asymptomatic malaria found differentially expressed genes, 99 of which
were upregulated and 135 of which were downregulated in CM. Further character-
ization of these genes revealed a large proportion of upregulated genes encoding
Plasmodium exported proteins and variant surface antigen proteins, such as PfEMP1
and RIFIN, and downregulated genes included those encoding rhoptry-associated
proteins, merozoite surface proteins, and Maurer’s cleft two-transmembrane do-
main protein (212).
(iii) Markers of parasite drug resistance. Resistance to antimicrobial agents, includ-
ing antimalarial drugs, is a growing problem (213, 214). Widespread resistance could set
back many of the gains made by malaria control initiatives over the last decade (11,
214). Artemisinin and its derivatives are the mainstay of antimalarial treatment globally,
and emerging resistance is starting to spread from foci in Southeast Asia (11, 214, 215).
Markers of artemisinin resistance were sought in a microarray-based transcriptomic
study of 1,043 P. falciparum clinical isolates from 13 regions of Southeast Asia and Africa
where malaria is endemic (216). The identiﬁcation of genes signiﬁcantly associated with
the parasite clearance half-life strongly implicated the parasite unfolded protein re-
sponse in mediating artemisinin resistance and also showed an association with
reduced expression levels of DNA replication genes, presumptively linked to relative
resistance in slower-developing early-blood-stage parasites.
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LEARNING FROM TRANSCRIPTOMIC STUDIES OF MALARIA
Key Insights
The ups and downs of type I interferons. The high frequency of AT-rich motifs in
Plasmodium genomes, such as the ATTTTTAC motif in P. falciparum, is implicated in the
induction of type I interferons (127). The role of type I interferons in malaria has been
enigmatic because of conﬂicting data from animal models indicating roles in both
protection and pathology (127, 142, 199, 217, 218). Emerging ﬁndings suggest that the
timing, source, and regulation of type I interferons are crucial (219), and it is interesting
to note that this might have been inferred earlier from data in the transcriptomic
literature. In humans and mice, type I interferon-related genes are consistently induced
in blood early in infection (in uncomplicated disease) (126, 127, 129, 173), but relative
downregulation is seen in later, more severe infection or with a higher parasite load
(129, 173, 187) (Fig. 3). Interestingly, this type I interferon signature is found in PBMCs
(127), whole blood (129, 173), and isolated neutrophils (220).
In contrast, increases in type I interferon-related gene expression levels in brain are
temporally associated with the onset of ECM (69, 144, 174, 175, 178, 179), whereas
higher early expression levels in spleen are associated with a better control of para-
sitemia (199), and sustained high expression levels in spleen are associated with ECM
(217). This ﬁts very well with the evolving paradigm, developed through functional
studies, that an early burst of type I interferons may be necessary to enhance innate
and adaptive responses, while sustained production may suppress pathological im-
mune responses but risks compromising the control of the parasite load (218, 219).
Thus, the timing of the up- and downregulation of type I interferon signaling deter-
mines a ﬁne balance between immunopathology and parasite survival, and inﬂuencing
this balance through the kinetics of AT-rich DNA release may have evolved as a parasite
strategy to manipulate the host response (142, 218).
Pathological effects of neutrophils. Neutrophils are one of the most numerous
leukocyte populations in blood, yet there has been disproportionately little investiga-
tion of their role in malaria. Higher neutrophil-associated gene expression levels are a
consistent feature of analyses of whole-blood transcriptomes from uncomplicated and
severe human disease (24, 126, 187). In contrast, the sparse data from rodent models
do not show an induction of a neutrophil-associated gene expression signature in
whole blood in ECM (173) but show an association with lung pathology (137). The
simplest explanation for these differences might result from changing proportions of
neutrophils in blood.
Relative neutrophilia is frequently described in human cases of malaria (221, 222),
particularly in association with severe disease and high-level parasitemia, whereas this
is not always the case in rodent malaria models. However, differences in neutrophil
counts are not the only explanation. In cases of retinopathy-positive CM, neutrophil
gene expression signatures were greatly increased in comparison to those in cases of
retinopathy-negative CM despite very similar neutrophil counts (187). Another expla-
nation may be genuine transcriptional differences between whole-blood neutrophil
populations, possibly arising from the mobilization of immature neutrophils from the
bone marrow. This may explain the particular enrichment of genes encoding neutrophil
granule proteins, being regulated during neutrophil development and particularly
expressed in immature neutrophils (223).
Consistent with this, immature neutrophils and elevated circulating levels of their
granule proteins are detected in cases of severe and uncomplicated malaria (221, 224).
Many neutrophil granule proteins can be damaging to host tissues, and it is tempting
to speculate that this indicates a pathogenic mechanism in humans. Female C57BL/6
mice, which are commonly used in malaria research, have among the lowest circulating
neutrophil counts of all mouse strains (225). Although neutrophil mobilization from
bone marrow has been described for rodent malaria (226, 227), neutrophil counts in
peripheral blood can go up or down (226–228), possibly reﬂecting the rate of egress
from bone marrow, trafﬁcking to other organs, and cell death.
Proving a functional role for neutrophils in rodent model pathogenesis, and extrap-
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olating the data to human disease, is also challenging. Antibody depletion of neutro-
phils has been used to assess their role, but common antibodies used for this purpose
can also deplete monocyte subpopulations (229, 230). Despite this, additional evidence
supports the roles of neutrophils in malaria-induced lung and liver injury (220, 228) and
of a neutrophil subpopulation in ECM (227). The prominence of neutrophil-related gene
expression in human cases of malaria clearly indicates that more work is needed to
understand exactly what these cells contribute to both defense and disease.
Variations in parasite gene expression in vivo. The broad similarity of in vivo and
in vitro parasite transcriptomes, particularly after accounting for the parasite develop-
mental stage, is discussed above. However, the amount of variation from the in vitro
“standard” that occurs in vivo remains to be fully quantiﬁed, as do the implications of
any in vivo variation. Differences in parasite gene expression detected between differ-
ent in vivo situations (117, 216), including those under antimalarial drug pressure,
suggest that the in vivo variation can be both substantial and responsive to the
within-host environment, even if, on average, it is similar to the in vitro situation. The
implications of such in vivo variation may be very important. The use of laboratory-
adapted parasites for high-throughput drug and antibody screens may either overes-
timate or miss in vivo effectiveness. Unfortunately, the factors that drive in vivo
variations are currently poorly deﬁned, but their characterization might allow the
adaptation of culture conditions to recreate elements of in vivo variability.
Closing Gaps in Knowledge: General Principles
How similar are animal models and human disease? Although it is clear that there
are differences between severe malaria in animal models and human disease (172, 180,
197), there is no agreed way to quantify the importance of the differences or similarities
for understanding pathogenesis. This is not unique to malaria research; similar contro-
versies arise for other infectious diseases, such as tuberculosis (231), meningococcal
disease (232), and typhoid (233). One way to objectively identify similarities would be
through systematic transcriptomic comparisons between species, across organs, at
different time points, and over the spectrum of severity (234). The easiest comparisons
in practice will be comparisons of blood transcriptomes between humans and rodent
models, as has been tried for tuberculosis (231), but comparisons with other tissues will
also be needed for a complete understanding (234). In this way, the components of a
model that have relevance to human disease may be identiﬁed and studied further,
even if other aspects of the model are different. Studies with outbred, wild-derived, or
true-wild mice may also be highly informative because the greater genetic variation
between these mice (235) may increase variations in gene expression associated with
variations in the parasite load, severity of anemia, or organ dysfunction at the same
time point during infection, recapitulating the variability found in humans.
Variation in pathogen genomes. The involvement of the highly polymorphic var, rif,
and stevor multigene families in the pathogenesis of severe malaria is attracting
increasing interest (19, 236), but accurately determining the expression levels of these
and other highly polymorphic genes in global gene expression analyses remains
challenging because of current reliance on a reference genome for the quantiﬁcation
of transcript levels. For bacterial pathogens, a similar challenge can arise through
different mechanisms, with the core genome potentially being supplemented by a
ﬂexible genome of additional genes present at various frequencies (237). The ﬂexible
genes may be acquired or lost by mutation and selection during the course of
population growth and by the transfer of genetic material between bacterial species.
One strategy for improving quantiﬁcation is a targeted approach sequencing just the
most abundant variant genes, as was recently applied to the P. falciparum var tran-
scriptome (192). A more comprehensive strategy would be complete genome and
transcriptome sequencing on the same pathogen isolates. Assembly would be facili-
tated by longer sequenced reads using, for example, MinION and PacBio sequencing
technologies (238, 239). Cost remains an issue for this approach, particularly because it
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would be important to collect as many clinical isolates as possible to obtain a complete
picture of their complexity and rigorously deﬁne associations with severity.
Are we sampling the right tissues? The most useful transcriptomic information
about the host response or host-pathogen interactions will likely be derived from RNA
extracted from speciﬁc tissues rather than bulk sampling of tissues. For example,
analysis of whole brain or whole spleen, composed of many cell types with differing
functions, may misrepresent speciﬁc interactions involved in protection or pathogen-
esis. Ideally, we would like to investigate much more speciﬁc in vivo interactions in
malaria (Fig. 1), for example, mosquito saliva, sporozoites, and skin; Kupffer cells,
hepatocytes, and sporozoites; hepatocytes, tissue schizonts, and CD8 lymphocytes; and
brain endothelial cells and sequestered parasites. Techniques are evolving for the
microscopic dissection and capture of speciﬁc cells from tissues and for the puriﬁcation
of single cells from blood and organs (36, 240) (Fig. 2). The combination of these
techniques with RNA-seq protocols suitable for histological specimens and low-
quantity RNA now opens the door to interrogating these interactions in great detail
(240).
Which clinical phenotypes should be studied? Future studies need to give careful
consideration to the information that might be gained from comparisons of different
clinical phenotypes. To better understand the pathogenesis of severe malaria, there is
a clear need for a dual RNA-seq analysis comparing cases of severe and uncomplicated
malaria. Deeper insights may be gained from comparisons of subjects with discrete
phenotypes of severe malaria, such as severe anemia, acidosis/hyperlactatemia, and
CM. Comparisons between subjects with malaria and subjects with asymptomatic
infection, matched for parasite loads, may be particularly helpful to understand the
nature of antidisease immunity.
Are we looking at the right stage of infection? Looking at events preceding the
onset of severe disease due to infection is necessary to understand the underlying
pathogenic mechanisms, but targeting these mechanisms when a patient presents with
severe disease may be ineffective because the damage has already been done. There
are notably no studies of malaria examining gene expression proﬁles associated with
recovery from severe disease, during the ﬁrst few days after the initiation of antimalarial
treatment, and such studies may be much more informative for the identiﬁcation of
targets for adjunctive therapies to improve outcomes of malaria and other infectious
diseases.
Association and causation. Within transcriptomic data sets, it is inevitable that the
expressions of many genes will be highly correlated with each other and with outcomes
of interest, and this makes it particularly difﬁcult to separate association from causation
in observational studies. We believe that there are approaches that might enhance the
identiﬁcation of causal relationships. One relatively simple approach is to look at
differences between different biological phenotypes of the outcome of interest. For
example, comparisons of uncomplicated malaria with each of the different phenotypes
of severe malaria (hyperlactatemia, CM, and severe anemia) may reveal gene expression
common to all severe phenotypes and gene expression speciﬁc to each one. Since the
severe phenotypes share many common risk factors, such as parasite load (13), we
would expect the genes speciﬁc for each phenotype to be more likely to have causal
relationships. Similarly, quantitative or dose-response relationships can be used to
identify those genes that are highly correlated with speciﬁc features, such as the
platelet count or lactate concentration.
Even stronger evidence may come from one of the most powerful epidemiological
methods for demonstrating causation, Mendelian randomization (241). This epidemi-
ological technique uses natural population variation in a gene with a known function
to examine the causal effect of exposure, usually requiring a large set of genotyped
samples. A seminal example is the use of the protective effect of sickle-cell trait against
developing malaria to demonstrate that malaria causes susceptibility to bacterial
infections in humans (242). A similar approach might be employed to estimate the
proportion of gene expression that is responsible for limiting the parasite load rather
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than occurring solely as a consequence of the parasite load. Sickle-cell trait or other red
cell polymorphisms that limit parasite growth independent of the host immune re-
sponse might be used as the instrumental variable.
Regardless of the approach, new hypotheses may be generated based on gene
expression data, which can be tested by using reductionist approaches in vitro or in
animal models for experimental validation. In humans, causality can be assessed
directly in interventional studies, with transcriptomics providing a means to elucidate
the mechanism of action of new treatments in clinical trials.
Lessons for Study Design and Analysis
It is clear that many studies on malaria had suboptimal elements in their design.
Principles for improving the design of malaria studies will also apply to many other
infectious diseases (Table 2). The overarching principle is that if a study is not designed
to answer the research question, no novel statistical approach and no amount of data
mining are likely to be able to answer the question. Community guidelines for both
microarray and RNA-seq reporting already exist and will likely evolve to keep track with
increasingly complex analytical approaches (243, 244).
TRANSCRIPTOMICS IN FUTURE HOST-PATHOGEN RESEARCH
Fifteen years of transcriptomic studies of malaria have brought many insights but
also highlighted the complexity and challenges of studying host-pathogen interactions
in this way. For other infectious diseases, some of these challenges may be even
greater. In the next decade, advances in transcriptomics will likely transform our
understanding of host-pathogen interactions in many infections. Speciﬁc examples
might include unraveling the triggers and consequences of bacterial toxin and protease
production in virulent staphylococcal and streptococcal infections; establishing the
mechanisms underlying clearance, latency, or progression in tuberculosis; and deﬁning
protective and harmful host-pathogen interactions in emerging infections, such as
Ebola and Zika viruses.
This will be facilitated by technical advances, such as long-read sequencing tech-
nologies and single-cell sequencing, that will allow unprecedented levels of detail to be
described. The greatest challenge may become the synthesis of the huge amounts of
data and detail into a model that is comprehensible to the human mind.
We believe that important insights will come from the integration of multiple layers
of data, such as transcriptomic, genomic, proteomic, and metabolomic data (1), com-
bined with comprehensive descriptions of clinical and other pathophysiological fea-
tures of infections. This will need to be done in increasingly large (and therefore costly)
studies, because the more layers of data that are integrated, the greater the dimen-
sionality. Methods for effectively reducing this dimensionality with minimal compro-
mise in discrimination will no doubt evolve in parallel. Usefulness and generalizability
will need to be maximized by the collection of consistent types of data between studies
so that their combination and meta-analyses can be performed.
To ensure the translation of discovery to clinical application, researchers will need to
better characterize the clinically relevant components of their model systems and
achieve optimal sampling of tissues with the most-relevant host-pathogen interactions.
This will require collaboration across disciplines, bringing transcriptomics together with
advances in imaging, minimally invasive sampling, microscopy, and viable-cell separa-
tion. Studies with humans will be greatly enhanced by embedding within formal
epidemiological studies with rigorous design principles. Clinical trials of antimicrobials
and adjunctive therapies represent rare opportunities where humans are subjected to
experimental manipulation, and collecting samples for transcriptomic analyses will be
helpful for mechanistic interpretations of their results.
Mathematical developments will likely facilitate new approaches to studying trajec-
tories of infectious diseases, overcoming the inherent limitation that naturally infected
human subjects present only a snapshot view of the dynamic process of infection (136).
Approaches have already been developed for fate mapping of single cells based on
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transcriptional similarities over a developmental continuum (245), and a similar ap-
proach may be taken to the course of human disease where the transcriptome of an
individual at a single point in time might be mapped onto a disease trajectory from
asymptomatic to mild to severe, by reference to the transcriptomes of each disease
state.
Transcriptomic studies fairly consistently show that different gene expression sig-
natures characterize infections with different pathogens and different stages of infec-
tion with the same pathogens (210, 211). This means that there is a high likelihood that
various selection methods applied to transcriptome analyses in any infectious disease
will reveal small sets of transcripts as diagnostic or prognostic biomarkers. This has the
potential to revolutionize many aspects of clinical infectious disease practice, if these
could be turned into rapid tests administered at the point of care. Currently, commer-
cial methods to allow these RNA signatures to be used as near-patient tests do not exist
(211), but as the potential impact of and demand for such methodologies are realized,
it seems inevitable that the technological problems will be solved.
In conclusion, we are optimistic about the advances in the understanding of
host-pathogen interactions that will come from future transcriptomic studies and the
beneﬁts that may come from these studies if they are well conducted. We predict that
the results of these studies will force researchers to consider much more dynamic
models of infection, where changes in the host response may affect pathogen behavior
and vice versa, and that the simultaneous study of host and pathogen will increasingly
be viewed as being essential.
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